Ndifor A M, Howells R E, Bray P G, Ngu J L, Ward S A
Department of Parasitology, Liverpool School of Tropical Medicine, United Kingdom.
Antimicrob Agents Chemother. 1993 Jun;37(6):1318-23. doi: 10.1128/AAC.37.6.1318.
A number of compounds, as exemplified by verapamil and desipramine, have been shown to enhance the susceptibility of resistant malaria parasites to chloroquine. The mechanism by which these agents reverse resistance is still controversial but is though to involve alterations in drug transport causing an increase in steady-state drug concentrations. We have proposed that an alternative resistance mechanism may involve the metabolic deactivation of the drug in some resistant parasites via cytochrome P-450 mixed-function oxidases. If the hypothesis is true, it should be possible to alter drug susceptibility in malaria parasites by the use of agents known to inhibit or induce cytochrome P-450 activities. We have assessed the ability of known inhibitors of cytochrome P-450 enzymes (cimetidine, metyrapone, and alpha-naphthoflavone) to enhance chloroquine susceptibility in Plasmodium falciparum culture-adapted and wild-type isolates in vitro and P. berghei in vivo. In all three systems, the inhibitor cimetidine enhanced parasite susceptibility to chloroquine, and this increase in susceptibility was unrelated to changes in chloroquine steady-state concentrations in vitro or to alterations in host pharmacokinetics in vivo. Additionally, the cytochrome P-450 inducer phenobarbital produced slight decreases in P. falciparum drug susceptibility in vitro. We have compared the ability of the cytochrome P-450 inhibitors cimetidine and metyrapone to enhance drug susceptibility with that of verapamil by using wild-type malaria isolates obtained from Cameroon. Verapamil completely reversed resistance, i.e., to below the cutoff point of 70 nM, in all the resistant isolates. Cimetidine enhanced chloroquine susceptibility in 60% of the isolates and reduced 50% inhibitory concentrations by at least 43% in all the resistant isolates. The compounds tested had little or no effect on the 50% inhibitory concentrations for the susceptible isolates. The data support a possible role for detoxification in chloroquine resistance, and even in the absence of such a process we have observed apparent chemosensitization by agents whose common biological feature is the inhibition of cytochrome P-450 enzymes. Additionally, sensitization has been observed in wild-type isolates of P. falciparum obtained form immune residents of an area of endemicity as well as culture-adapted parasites.
许多化合物,如维拉帕米和地昔帕明,已被证明可增强抗氯喹疟原虫对氯喹的敏感性。这些药物逆转耐药性的机制仍存在争议,但据认为涉及药物转运的改变,导致稳态药物浓度增加。我们提出,另一种耐药机制可能涉及某些耐药疟原虫通过细胞色素P - 450混合功能氧化酶对药物的代谢失活。如果该假设成立,那么通过使用已知能抑制或诱导细胞色素P - 450活性的药物,应该有可能改变疟原虫对药物的敏感性。我们评估了已知的细胞色素P - 450酶抑制剂(西咪替丁、美替拉酮和α - 萘黄酮)在体外增强恶性疟原虫适应培养和野生型分离株以及体内伯氏疟原虫对氯喹敏感性的能力。在所有这三个系统中,抑制剂西咪替丁增强了疟原虫对氯喹的敏感性,而这种敏感性的增加与体外氯喹稳态浓度的变化或体内宿主药代动力学的改变无关。此外,细胞色素P - 450诱导剂苯巴比妥在体外使恶性疟原虫的药物敏感性略有降低。我们通过使用从喀麦隆获得的野生型疟原虫分离株,比较了细胞色素P - 450抑制剂西咪替丁和美替拉酮与维拉帕米增强药物敏感性的能力。维拉帕米在所有耐药分离株中完全逆转了耐药性,即降至70 nM的截止点以下。西咪替丁在60%的分离株中增强了氯喹敏感性,并且在所有耐药分离株中将50%抑制浓度降低了至少43%。所测试的化合物对敏感分离株的50%抑制浓度几乎没有影响。这些数据支持了解毒在氯喹耐药性中可能起的作用,并且即使在没有这种过程的情况下,我们也观察到具有抑制细胞色素P - 450酶这一共同生物学特征的药物出现了明显的化学增敏作用。此外,在从疟疾流行地区的免疫居民获得的恶性疟原虫野生型分离株以及适应培养的寄生虫中也观察到了增敏现象。